Search research articles
Contact Us
Filters
Showing results (31-40 of 103) with videos related to
Page
of 11
Sort By:
Journal of Gastrointestinal Oncology
|
June 2, 2015
Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction
Raed Al-Rajabi, Sukeshi Patel, Norma S Ketchum, et al.
Molecular Cancer Research : MCR
|
August 31, 2013
Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression
Pramod S Gowda, Jianhong D Deng, Sweta Mishra, et al.
Cancers
|
June 20, 2019
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
Devalingam Mahalingam, Julio Peguero, Putao Cen, et al.
Cancers
|
June 29, 2019
Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
Devalingam Mahalingam, Jennifer S Carew, Claudia M Espitia, et al.
Journal of Cellular and Molecular Medicine
|
November 25, 2010
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Kevin R Kelly, Jeffrey Ecsedy, Ernest Medina, et al.
Cancer Chemotherapy and Pharmacology
|
March 15, 2017
A phase II study of REOLYSIN<sup>®</sup> (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma
Devalingam Mahalingam, Christos Fountzilas, Jennifer Moseley, et al.
British Journal of Cancer
|
June 23, 2022
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, et al.
Investigational New Drugs
|
January 20, 2017
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Christos Fountzilas, Selena Stuart, Brian Hernandez, et al.
Oncotarget
|
November 18, 2015
Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer
Sweta Mishra, Qin Tai, Xiang Gu, et al.
The Journal of Biological Chemistry
|
December 15, 2010
Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis
Jennifer S Carew, Claudia M Espitia, Juan A Esquivel, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 103) with videos related to
Sort By:
Page
of 11
Journal of Gastrointestinal Oncology
|
June 2, 2015
Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction
Raed Al-Rajabi, Sukeshi Patel, Norma S Ketchum, et al.
Molecular Cancer Research : MCR
|
August 31, 2013
Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression
Pramod S Gowda, Jianhong D Deng, Sweta Mishra, et al.
Cancers
|
June 20, 2019
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
Devalingam Mahalingam, Julio Peguero, Putao Cen, et al.
Cancers
|
June 29, 2019
Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
Devalingam Mahalingam, Jennifer S Carew, Claudia M Espitia, et al.
Journal of Cellular and Molecular Medicine
|
November 25, 2010
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
Kevin R Kelly, Jeffrey Ecsedy, Ernest Medina, et al.
Cancer Chemotherapy and Pharmacology
|
March 15, 2017
A phase II study of REOLYSIN<sup>®</sup> (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma
Devalingam Mahalingam, Christos Fountzilas, Jennifer Moseley, et al.
British Journal of Cancer
|
June 23, 2022
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, et al.
Investigational New Drugs
|
January 20, 2017
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Christos Fountzilas, Selena Stuart, Brian Hernandez, et al.
Oncotarget
|
November 18, 2015
Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer
Sweta Mishra, Qin Tai, Xiang Gu, et al.
The Journal of Biological Chemistry
|
December 15, 2010
Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis
Jennifer S Carew, Claudia M Espitia, Juan A Esquivel, et al.
Page
of 11